News for Race Oncology Limited (RAC.AX)

The ASX200 has been flat, down 0.1% at 7,812 points in early…

The ASX has been up 0.45% at 7,783 points, breaking its losing…

Race Oncology Ltd has received approval to go ahead with its Phase I trial to assess R220 and begin enrolling patients

The leader of the free world's desire to be the centre of all attention has once again tanked markets. Fatigue is inevitable

The ASX200 closed up 0.15% at 8,474 points. Bitcoin broke through US$100,000 for the very first time after climbing 6.9%.

The ASX200 has been down 0.1% at 8,317 points.The local bourse pared early gains and has been trading flat in the afternoon.

Race Oncology Ltd has completed a successful drug discovery program started in 2022 at Monash University in Melbourne

The ASX200 closed down 0.17% at 8,071 points as the market awaits local inflation data for July tomorrow.

The ASX200 had a turnaround, closing the week down 0.12%. Health Care led sector gains, up three quarters of a per cent, driven by top performers including Clinuvel, Race Oncology, and Immutep. On the other end, Materials and Financials suffered the worst losses, down 0.5% and 0.45% respectively.

The ASX 200 dropped hard this morning, and is struggling to make headway after shock inflation figures spooked investors yesterday.

The ASX 200 has finished the day up a per cent, after the RBA kept interest rates on hold at 4.35%, firmly in line with predictions.

Race Oncology (ASX:RAC) has announced a preclinical breakthrough in heart toxicity side…

Race Oncology (ASX: RAC) has achieved a significant breakthrough with the US Food and Drug Administration (FDA) awarding orphan drug designation (ODD) to

Pharmaceutical companies can bring new hope to patients by delivering solutions to unmet medical needs. They can go from small market cap plays to market giants – but getting there isn't easy, it’s risky, and it can take a lot of money and patience. Hosted by HotCopper and The Market Online's executive producer Sonia Madigan, this webinar demystifies the clinical trials & approvals process.

The ASX200 closed the day down XXXX. Aside from consumer discretionary and healthcare, all other sectors ended in the red.

The ASX200 is tracking lower than expected, down nearly a quarter of…

The ASX200 closed .4 of a per cent down, with IT stocks weighing on the market and energy making marginal gains.

The ASX200’s been trading down a quarter of a per cent – even further than expected. The utilities and financials sectors are in the lead.

The ASX200 is set to fall with futures down -0.13% near 8.30am AEDT on Wednesday. US markets pared recent gains again overnight.